African Panel Challenges Fitch's Afreximbank Ratings Downgrade
An African Union-backed panel challenged Fitch Ratings to review its downgrade of the African Export-Import Bank's rating, questioning the company's classification of loans to three countries.
Fitch cut its assessment of Afreximbank's debt closer to junk earlier this week, citing the risk that money owed to the lender by sovereign borrowers might be included in those nations' debt restructurings. The downgrade reduced the bank's rating to BBB- — one step above the speculative level that would limit the pool of funds allowed to invest in its debt.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
3 Highly-Rated Dividend Stocks You've Probably Never Heard Of (But Should)
When it comes to dividend investing, selecting the right stock often means choosing the largest, most consistent, most secure, and most popular companies in their respective fields. I'm talking about the Coca-Colas and the Abbotts of the world - time-tested names that have the balance sheets, brand strength, and operational base to weather economic storms while still paying (and increasing) their dividends. However, more adventurous income investors might want to explore riskier stocks that are often overlooked. Smaller-cap companies, while not household names or industry leaders, may still offer consistent yields at more attractive levels. Such stocks, however, can be a hit or miss - unless you look for the best ones that meet the right criteria. 3 ETFs with Dividend Yields of 12% or Higher for Your Income Portfolio 3 Highly-Rated Dividend Stocks You've Probably Never Heard Of (But Should) Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. So, today, let's explore the lesser-known, Wall-Street-approved dividend stocks in the market to find which ones offer consistent payouts and the best yields. With Barchart's Stock Screener tool, I added the following filters: Number of Analysts: 8 to 12. I'll limit the final list to stocks that Wall Street covers, but not excessively. The 8-12 range is best suited for that situation. Current Analyst Rating: 4.5 to 5 (Strong Buy). I want only the best of the best on this list to improve the chances of success. Dividend Payout Ratio: 25% to 60%. The dividend payout ratio is the portion of the company's earnings that is used to pay dividends. A range of 25% to 60% represents a reasonable balance between relatively high yields and sufficient funds to support business growth and improvement - something that long-term investors would appreciate. Market Cap: $3 billion to $10 billion. This filter limits my search to mid-cap companies, which are often ignored in top dividend stock lists. Annual Dividend Yield: 0.01% and above. With the filters in place, I ran the screen and got the following results: The screen yielded 13 companies. From there, I arranged the results in order from highest to lowest TTM dividend yield, then checked the top ones for dividend consistency. Thankfully, the top three had regular dividend payments, so I chose all of them to discuss today. I've featured Rithm Capital before in a 'highest-yielding dividend stock' analysis, and I'm happy to say that it retains that title. The REIT provides mortgage servicing, asset management, and originations in the US. Its subsidiaries include NewRez, Genesis Capital, Guardian Asset Management, GreenBard, and Sculptor, which round out its expansive investment platform across various businesses. Rithm Capital offers a stable quarterly dividend of 25 cents per share since 2021, which translates to a $1.00 annual rate and an 8.9% yield. Based on its 43.01% dividend payout ratio, the company has sufficient funds to continue paying dividends. RITM stock has an impressive 4.80 average analyst score, indicating a strong buy rating based on 10 individual analyst reviews. It's also trading well below its pre-pandemic price levels, which potentially offers significant growth if it fully recovers. Next on the list is Copa Holdings, a South American airline holding company that operates the Copa Airlines, AeroRepublica, and Wingo brands. The company offers around 375 daily scheduled flights to 32 countries across all of its businesses. It is one of the top airlines in Latin America, and its cheaper offerings through Wingo make it an attractive choice for budget-conscious travelers. According to its latest financials, Copa pays a $1.61 quarterly dividend, which translates to $6.44 per share per year, and translates to a high 6.02% yield. The company has a relatively safe payout ratio of 43.98% and one of the highest analyst scores I've recently seen - 4.91 based on 10 reviews - and an attractive high target price of $190, which represents an 83% potential upside. Last but not least is Nexstar Media Group, one of the largest local TV broadcast groups in the U.S.. The company has a TV station presence in almost all US states, and it also owns The CW Network, the fifth-largest broadcast network in the country and one of the most prolific networks in terms of scripted TV content for younger audiences. I'm willing to bet top dollar that practically everyone in the U.S. reading this has heard of or seen something from The CW. Nexstar Media Group pays $1.86 quarterly, which translates to a $7.44 annual rate and a decent 4.46% yield. NXST stock also maintains a strong buy rating with an average score of 4.75. While I firmly believe that income investors should have some of the top dividend stocks from the Dividend Kings and Aristocrats lists, like KO, ABT, JNJ, and PEP, there's no hard and fast rule against investing in smaller dividend stocks with attractive yields. That said, smaller-cap companies tend to be at a higher risk of experiencing significant price fluctuations. But, if you get lucky, you might just snag a high-yield dividend stock while it's on its way to mega-cap status. On the date of publication, Rick Orford did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
SoundHound AI, Inc. (SOUN) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, SoundHound AI, Inc. (SOUN) closed at $9.57, marking a +1.59% move from the previous day. This change outpaced the S&P 500's 0.22% loss on the day. Meanwhile, the Dow experienced a rise of 0.08%, and the technology-dominated Nasdaq saw a decrease of 0.51%. The company's stock has dropped by 1.36% in the past month, falling short of the Computer and Technology sector's gain of 2.98% and the S&P 500's gain of 0.45%. Market participants will be closely following the financial results of SoundHound AI, Inc. in its upcoming release. It is anticipated that the company will report an EPS of -$0.06, marking a 45.45% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $33.03 million, reflecting a 145.36% rise from the equivalent quarter last year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.16 per share and a revenue of $161.82 million, indicating changes of +84.62% and +91.07%, respectively, from the former year. Investors should also pay attention to any latest changes in analyst estimates for SoundHound AI, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, SoundHound AI, Inc. boasts a Zacks Rank of #3 (Hold). The Computers - IT Services industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 87, positioning it in the top 36% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report SoundHound AI, Inc. (SOUN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $5.03, demonstrating a -1.57% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.22%. Meanwhile, the Dow gained 0.08%, and the Nasdaq, a tech-heavy index, lost 0.51%. Coming into today, shares of the biotechnology company had gained 23.28% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 0.45%. Market participants will be closely following the financial results of Recursion Pharmaceuticals in its upcoming release. In that report, analysts expect Recursion Pharmaceuticals to post earnings of -$0.34 per share. This would mark year-over-year growth of 15%. In the meantime, our current consensus estimate forecasts the revenue to be $15.58 million, indicating a 8.02% growth compared to the corresponding quarter of the prior year. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$1.34 per share and a revenue of $74.95 million, representing changes of +20.71% and +27.38%, respectively, from the prior year. It's also important for investors to be aware of any recent modifications to analyst estimates for Recursion Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.19% higher. Recursion Pharmaceuticals is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 87, placing it within the top 36% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
